Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Chugai, Taisho Toyama to Offer Compliance Advantages with Once-Monthly Bonviva
September 3, 2013
- MTPC’s SGLT-2 Inhibitor Canagliflozin Now No. 1 in Prescription Share in US, Overtaking Januvia
September 3, 2013
- Astellas Paid 19.3 Billion Yen to Healthcare Professionals, 7.1 Billion Yen for Information Provisioning in FY2012
September 3, 2013
- Takeda’s OBLEAN Near-Certain to Debut as Japan’s 1st Anti-Obesity Drug in 20 Years
September 2, 2013
- Daiichi Sankyo Provided 36.6 Billion Yen to Physicians, Medical Institutions in FY2012, 22.7 Billion Yen for R&D
September 2, 2013
- US FDA Requests Additional Data for Tolvaptan for Treatment of ADPKD: Otsuka
September 2, 2013
- Orphan Drug Wholesaler S.D. Next to Swing into Black in FY2015 with Tailored Distribution Services: Pres.
August 30, 2013
- WHO Grants Prequalification to Eisai for Lymphatic Filariasis Treatment
August 30, 2013
- New Products Shake Up Market for Osteoporosis Treatments; Entry of Pralia Could Lead to Change in Market Structure
August 30, 2013
- AnGes MG’s CIN Therapeutic Vaccine Project Picked for Health Ministry’s Research Grants
August 29, 2013
- Merck Serono’s Northeast Asian Development Zeros in on 4 Cancer Types: R&D Site Head
August 29, 2013
- Eisai Launches Higher-Dose Aricept 23 mg Tablet in South Korea
August 29, 2013
- Shionogi Paid a Total of 10.2 Billion Yen to Healthcare Professionals, 1 Billion for Research Grants
August 28, 2013
- Takeda Initiates Overseas PIII Trial of Actos for Delaying the Onset of MCI Due to Alzheimer’s Disease
August 28, 2013
- Takeda to Appoint Mr Roger as CFO
August 28, 2013
- Livalo AG Skips NHI Price Listing Again, Sandoz Won’t Comment on Diovan AG
August 27, 2013
- Astellas Launches Tacrolimus Extended-Release Capsules Astagraf XL in US
August 27, 2013
- LEO Pharma Files NDA for Psoriasis Drug, Paving Way for Full Foray into Japan Market
August 27, 2013
- Announcement: Oncology Japan 2013 to Be Held on November 5, 6
August 27, 2013
- Affinity Gel Market to Triple in 2017: Fuji Chimera Research Institute
August 26, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…